JPMorgan: We Know More About Moderna Now — But Don’t Like It Any Better, , on October 9, 2020 at 8:24 pm

Financial News
By
On October 9, 2020
In Financial News
Tags:

Vaccine specialist and COVID-19 antagonist Moderna (MRNA) had a busy Thursday, issuing press releases and holding conference calls to discuss what it had said in the press releases already.Three major subjects for discussion were covered over the course of the day, and in a note updating investors on its opinion of Moderna, JPMorgan analyst Cory Kasimov discussed them all. Let’s begin with the most urgent question of the day: Coronavirus, and Moderna’s mRNA-1273 vaccine to prevent getting infected with it.Kasimov notes that Moderna unveiled “a few incremental data points” on its COVID-19 vaccine. Moderna is looking to get, and disclose its first “interim” data sometime next month, and then to have a second set of data ready a month or two later. However, the updates “do little to change our view of the stock,” says Kasimov, and so JP Morgan still feels “most comfortable on the sidelines.” Hence, the analyst’s Neutral rating remains unchanged. (To watch Kasimov’s track record, click here)Nonetheless, moving on to the other news items, Kasimov notes that Moderna’s partnership with Merck to develop the mRNA-1172 vaccine against adult respiratory syncytial virus (RSV — a common virus that can lead to pneumonia or other severe symptoms, especially in patients who are elderly or have an underlying health condition), is on the rocks. Just as soon as the vaccine finishes up its Phase 1 clinical trials, Merck will return “all rights” to RSV vaccines to Moderna, and focus its own efforts on antibodies against the disease instead. Meanwhile, Moderna will focus on an mRNA-1345 RSV vaccine.Kasimov comments that while this is not necessarily bad news for Moderna, “it is rarely ever a good thing when” a partner voluntarily pulls out of a collaboration at this point in a clinical trial. The fact that Moderna will shift its own efforts away from mRNA-1172, and towards a different RSV vaccine, tends to support this interpretation of events.Last but not least: DARPA. In a separate press release Thursday, Moderna advised that the U.S. Defense Advanced Research Projects Agency has awarded it up to $56 million “to fund development of a mobile manufacturing protype” for on-site vaccine production.Of course, one of the big logistical problems with deploying upcoming coronavirus vaccines is going to be how to keep the vaccines “fresh” between the time they’re manufactured and the time they’re administered to patients. Moderna’s idea to solve this problem, especially in locales where it might be difficult to maintain refrigeration (say, in developing nations), is “to develop a mobile, end-to-end automated manufacturing platform to provide in-field, just-in-time manufacturing of… vaccines.”DARPA is going to give Moderna the money it needs to try and prove it can do this in a min-factory measuring just six feet cubed.Kasimov didn’t have much to say on this point, mind you. But another analyst, Oppenheimer’s Hartaj Singh, called the idea “an added step toward establishing mRNA vaccines as a best-in-class prophylactic approach to addressing infectious diseases.”And not for nothing, but Singh thinks Moderna stock will outperform the market — and is worth $108 a share. (To watch Singh’s track record, click here)Overall, with 13 analyst reviews on record, split into 10 Buys, 2 Holds, and 1 Sell, Moderna has a Moderate Buy consensus rating. Meanwhile, the average price target of $92.77 implies a 27% upside from current level. (See Moderna stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

JPMorgan: We Know More About Moderna Now — But Don’t Like It Any BetterVaccine specialist and COVID-19 antagonist Moderna (MRNA) had a busy Thursday, issuing press releases and holding conference calls to discuss what it had said in the press releases already.Three major subjects for discussion were covered over the course of the day, and in a note updating investors on its opinion of Moderna, JPMorgan analyst Cory Kasimov discussed them all. Let’s begin with the most urgent question of the day: Coronavirus, and Moderna’s mRNA-1273 vaccine to prevent getting infected with it.Kasimov notes that Moderna unveiled “a few incremental data points” on its COVID-19 vaccine. Moderna is looking to get, and disclose its first “interim” data sometime next month, and then to have a second set of data ready a month or two later. However, the updates “do little to change our view of the stock,” says Kasimov, and so JP Morgan still feels “most comfortable on the sidelines.” Hence, the analyst’s Neutral rating remains unchanged. (To watch Kasimov’s track record, click here)Nonetheless, moving on to the other news items, Kasimov notes that Moderna’s partnership with Merck to develop the mRNA-1172 vaccine against adult respiratory syncytial virus (RSV — a common virus that can lead to pneumonia or other severe symptoms, especially in patients who are elderly or have an underlying health condition), is on the rocks. Just as soon as the vaccine finishes up its Phase 1 clinical trials, Merck will return “all rights” to RSV vaccines to Moderna, and focus its own efforts on antibodies against the disease instead. Meanwhile, Moderna will focus on an mRNA-1345 RSV vaccine.Kasimov comments that while this is not necessarily bad news for Moderna, “it is rarely ever a good thing when” a partner voluntarily pulls out of a collaboration at this point in a clinical trial. The fact that Moderna will shift its own efforts away from mRNA-1172, and towards a different RSV vaccine, tends to support this interpretation of events.Last but not least: DARPA. In a separate press release Thursday, Moderna advised that the U.S. Defense Advanced Research Projects Agency has awarded it up to $56 million “to fund development of a mobile manufacturing protype” for on-site vaccine production.Of course, one of the big logistical problems with deploying upcoming coronavirus vaccines is going to be how to keep the vaccines “fresh” between the time they’re manufactured and the time they’re administered to patients. Moderna’s idea to solve this problem, especially in locales where it might be difficult to maintain refrigeration (say, in developing nations), is “to develop a mobile, end-to-end automated manufacturing platform to provide in-field, just-in-time manufacturing of… vaccines.”DARPA is going to give Moderna the money it needs to try and prove it can do this in a min-factory measuring just six feet cubed.Kasimov didn’t have much to say on this point, mind you. But another analyst, Oppenheimer’s Hartaj Singh, called the idea “an added step toward establishing mRNA vaccines as a best-in-class prophylactic approach to addressing infectious diseases.”And not for nothing, but Singh thinks Moderna stock will outperform the market — and is worth $108 a share. (To watch Singh’s track record, click here)Overall, with 13 analyst reviews on record, split into 10 Buys, 2 Holds, and 1 Sell, Moderna has a Moderate Buy consensus rating. Meanwhile, the average price target of $92.77 implies a 27% upside from current level. (See Moderna stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage